Project Details
Description
A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
| Status | Active |
|---|---|
| Effective start/end date | 6/1/15 → 12/30/23 |
Funding
- Altor BioScience Corporation
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.